Rosiglitazone prescribing information updated

January 28, 2008 on 9:57 am | In Prescribing Extra - Drugs | Print Print |

The European Medicines Agency (EMEA) has recommended (PDF) new warnings and contraindications for rosiglitazone after it adopted the October 2007 findings of the Committee for Medicinal Products for Human Use (CHMP).

The CHMP recommended that rosiglitazone:

  • Must not be used in patients with an acute coronary syndrome, such as angina or some types of myocardial infarction
  • Should be avoided in patients with ischaemic heart disease and/or peripheral arterial disease

These new warnings are more restrictive than previous advice that recommended careful evaluation of the patient’s individual risk.

Action: Clinicians should be aware of these new recommendations and ensure that patients who remain on treatment with rosiglitazone are not contraindicated following this update.

Copyright ©2008 Prescribing Advice for GPs

1 Comment »

RSS feed for comments on this post. TrackBack URI

  1. [...] the withdrawal of dydrogesterone (Duphaston/Duphaston HRT®) for commercial reasons and the new contraindications and warnings added to the prescribing information for [...]

    Pingback by Prescribing Advice for GPs » Drug Safety Update, Issue 7 — February 5, 2008 #

Leave a comment

XHTML: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS Feed for New Entries.
Akismet has protected Prescribing Advice for GPs from 3,097 spam comments.